Close Menu

esophageal cancer

Its CEO said the firm wants to make its tissue classifier the clinical standard for stratifying patients at risk of getting esophageal cancer.

Illumina Ventures was the sole investor in the Series A1 round, which will go toward Cernostics' clinical and market development studies for its TissueCypher Barrett's Esophagus assay.

Eleven new recommendations were issued to address appropriate HER2 testing and clinical guidance in individuals with advanced gastroesophageal adenocarcinoma.

Pages